TD Cowen initiated coverage of Nanobiotix (NBTX) with a Buy rating and no price target Nanobiotix’s physics-based platform technologies have broad applicability free of biological constraints, the analyst tells investors in a research note. TD sees upside in the shares as the company expands into more tumor types.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix: Differentiated Radiotherapy Enhancer, J&J Partnership, and Multi-Indication Pipeline Undervalue Long-Term Upside, Supporting Buy Rating
- Undervalued Royalty Stream and De‑Risked Partnership Economics Underpin Nanobiotix Buy Rating
- Nanobiotix Announces Share Capital and Voting Rights Update as of November 30, 2025
- Nanobiotix Joins CAC Mid 60 and SBF 120 Indices